Test No.: 840858 

7 a <=> yti)3 

Protection of Health 

and Environment 

GU 2.3 

Experimental Pathology 

NUCLEUS ANOMALY TEST IN SOMATIC INTERPHASE NUCLEI OF 

CHINESE HAMSTER 

Test material: TK 12 443 (TINUVIN 234) 

Date: February 11, 1985 

This document is directed to USEPA pursuant the Toxic Substances Control Act (TSCA). This document is the 

property of the sponsor and may be used only for that purpose intended by the sponsor and as authorized under 

applicable law. Every other or additional use, exploitation, reproduction, publication or submission to other 

parties requires the written permission of the sponsor, except as otherwise required by applicable law (e.g., TSCA). 

The use of these studies/documents for regulatory, registration or other commercial purposes [including but not 

limited to Registration, Evaluation, Authorization and Restriction of Chemical Substances (REACH)], without the 

express written permission of the sponsor is unauthorized and strictly prohibited.
- 2 -

INDE X 

General 

Summary and Assessment 

Procedure 

Results 

Literature 

Page 2 

Page 4 

Page 6 

Page 9 

Page 9 

GENERAL 

Type of stu(3y: 

Animal species: 

Purpose: 

Test material: 

Batch NO.: 

Purity: 

Validity: 

Stability: 

Sponsor: 

Testing facility: 

Personnel: 

Nucleus anomaly test 

Chinese hamster (Cricetulus griseus) random outbred strain, 

Evaluation of any mutagenic 

effect on somatic interphase 

cells by short term treatment as 

manifested by nucleus anomalies, 

TK 12 443 (TINUVIN 234) 

EN 02885.32 

Commercial grade 

Information provided by sponsor 

by request 

Ensured by sponsor 

Technical conduct:

Investigations of the slides: 

Statistics: , 
- 3 -

Test No.: 

Route of administration: 

Dosage: 

No. of animals per group: 

840858 

Oral by stomach tube 

1250, 2500, 5000 mg/kg 

In the tolerability test: 2 59 

and 2 <S6, in the mutagenicity 

test: 6 25 and 6 66 . 

Starting date (first administration): 

October 1, 1984 

Date of study completion: December 17, 1984 

Reported and filed: February 1985 

Location of archives: 
- 4 -

SUMMARY AND ASSESSMENT 

TK 12 443 (TINUVIN 234) was administered by gavage. 

Treatment consisted of one daily dose of 1250, 2500 or 

5000 mg/kg on each of two consecutive days. The animals were 

sacrificed 24 h after the second application. From the bone 

marrow smears were made. 

The experiment was performed to evaluate any mutagenic 

effect on somatic interphase cells in vivo. Mutagenic 

effects present themselves in interphase cells in form of 

nucleus anomalies of bone marrow cells (Lit.1,2). These anomalies occur in interphase cells as a consequence of damage 

during the mitotic process. The increase in anomalies shows 

a clear dose dependency, comparable to the occurrence of 

chromosome aberrations in metaphase preparations (Lit.3). 

The bone marrow smears from animals treated with the various 

doses of TK 12 443 showed no significant difference from the 

control. The incidence of bone marrow cells with anomalies 

of nuclei corresponds to the frequency observed in the control group. 

By contrast, a "positive control" experiment with cyclophosphamide (128 mg/kg) yielded 9.42% cells with anomalies of 

nuclei. This is significantly different from the controls 

(0.033) treated with the vehicle (0.5% CMC) alone. 
- 5 -

It is concluded that under the conditions of this experiment, no evidence of mutagenic effects was obtained in Chinese hamsters treated with TK 12 443, 

study director:

Date: February 6, 19 85 

Report reviewed 

and approved by:

Date: February 11, 19 85 
- 6 -

PROCEDURE 

1, Data on the animals used 

Chinese hamsters (Cricetulus griseus) of either sex 

(Q'.6 = 1:1) (weight 99 21-27 g, 66 21-27 g (tolerability 

test), 99 22-30 g, 66 20-34 g (mutagenicity test); age 

99 6-10 weeks, 66 4-9 weeks) were used. Standard diet: 

NAFAG No,924, Tap water ad libitum. The animals were kept 

in an air-conditioned room at a temperature of 23-24 C 

and a relative humidity of 56-57%, The room was illuminated for 12 hours daily. Identification of the animals by 

individual caging. 

2, Tolerability test 

A preliminary test was performed to determine the highest 

dosage of the test substance to be applied in the mutagenicity assay. 

Three groups of four Chinese hamsters (2 99 and 2 66) are 

treated with three different doses, one receiving the 

maximum dose of 5000 mg/kg, or the highest applicable 

dose, and the other two doses of 1/5 and 1/25 of that 

amount respectively. In the first part of the tolerability test the animals are treated with a single dose. The 

observation period corresponds to the interval between 

administration and sacrifice of the animals in the mutagenicity test, plus one day. If all animals in all dose 

groups die in the first step, a second test is performed 

in which the highest dose given is 3/4 of the lowest used 

in the preceding test. If some of the animals in one of 

the dose groups die, the test is continued with a high 

dose corresponding to a predetermined fraction of that 

dose. The highest dose survived by all animals in the 

group is used in the second part of the tolerability 

test. 
- 7 -

In this second part, the animals are treated according to 

the scheme used in the mutagenicity test, i.e, with two 

consecutive doses. The observation period corresponds to 

the interval between administration and sacrifice of the 

animals, plus one day. The highest dose is that determined in the first part of the test, and the further 

doses correspond to 2/3 and 1/3 of that amount. Depending 

on the outcome the highest dose causing no deaths is used 

as the highest in the mutagenicity test, or if necessary 

the test is repeated with lower doses. 

In this experiment the dose of 5000 mg/kg was determined 

as the highest applicable in the mutagenicity assay, together with further two doses, diminishing by a factor 

of 0,5, 

3. Treatment schedule in the mutagenicity test 

The preparation was administered orally to groups of 6 

female and 6 male animals each. Treatment consisted of 

daily one application pn 2 consecutive days, 24 h after 

the second application the animals were sacrificed by 

dislocation of the cervical vertebrae, 

a) TK 12 443: 1250, 2500 and 5000 mg/kg in 

20ml/kg vehicle. 

Vehicle: 0,5% aqueous solution of sodium-carboxymethylcellulose (CMC). 

b) Cyclophosphamide (ENDOXAN®): 128 mg/kg in 20 ml/kg 

0,5% CMC (positive control). 

Manufacterer of ENDOXAN®: ASTA-Werke, Germany, 

c) 20 ml/kg 0,5% CMC (negative control). 

Manufacturer of CMC: Hercules Comp,, U,S,A, 

4, Preparation of bone marrow 

Bone marrow was harvested from the shafts of both femurs. 

In a siliconized pipette filled with approx, 0,5 \il rat 

serum the bone marrow was drawn up. In order to receive 
- 8 -

a homogeneous suspension the content of pipette was aspirated gently about three times. Small drops of the mixture were transferred on the end of a slide, spread out 

by pulling it behind a polished cover glass and the preparations were air-dried. Three hours later, the slides 

were stained in undiluted May-Griinwald solution for 2 min 

then in May-Griinwald solution/water 1/1 for 2 min and 

then in Giemsa's, 40% for 20 min. After being rinsed in 

methanol 55% for 5-8 sec and washed off twice in water, 

they were left immersed in water for approx, 2 min. After 

rinsing with distilled water and air-drying, the slides 

were cleared in Xylene and mounted in Eukitt, 

5, Scoring of the slides 

The slides of three female and three male animals each of 

the negative control group, the positive control group 

and of the groups treated with various doses of 

TK 12 443 were examined, 1000 bone marrow cells each 

were scored per animal and the following anomalies were 

registered: 

a) Single Jolly bodies, b) fragments of nuclei in erythrocytes, c) micronuclei in erythroblasts, d) micronuclei in leucopoietic cells, e) polyploid cells, 

6, Statistics 

2 The significance of difference was assessed by X -test. 
- 9 -

RESULTS 

(Table 1) 

In all dosage groups the percentage of cells displaying anomalies of nuclei did not differ significantly from the negative control. 

By contrast, the positive control (cyclophosphamide, 

128 mg/kg) yielded a marked increase of the percentage of 

cells with anomalies. Here the mean percentage of anomalies 

was 9.42, whereas the negative control yielded a percentage 

of 0.033. The difference is highly significant (p< 0.05). 

REFERENCES 

BOLLER, K. and W. Schmid (1970), Chemische Mutagenese beim 

Sauger. Das Knochenmark des Chinesischen Hamsters als in 

vivo-Testsystem. Hamatologische Befunde nach Behandlung mit 

Trenimon, 

Humangenetik ii, 35-54. 

2 

MATTER, B, and W, SCHMID (1971), Trenimon-Induced Chromosomal Damage in Bone Marrow Cells of Six Mammalian Species, 

Evaluated by the Micronucleus Test. 

Mutation Res. 12 , 417-425, 

•^MULLER, D,, M, LANGAUER, R, RATHENBERG, F,F, STRASSER and 

R. HESS (1972), Mikrokerntest sowie Chromosomenuntersuchungen an somatischen und gonosomalen Zellen des Chinesischen Hamsters nach Cyclophosphamidgabe, 

Verh, Dtsch, Ges, Path, S^, 381-384, 
Tabl e 1 

THE EFFECT OF TK 12 

CHINESE HAMSTER 

Animals sacrifice d 

.. 

Contro l 

(0.5 % CMC) 

C:y c l oph o spham i d e 

(12 8 mg/kg ) 

/' 

TK 12 44 3 

(125 0 mg/kg ) 

TK 12 44 3 

(250 0 mg/kg ) 

TK 12 44 3 

(500 0 mg/kg ) 

4 4 3 

24 h 

Perc e 

M 

rH 

!S 

g 

-H 

C 

ta 

m 

o 

u Q) 

j Q 

^ 3 2 

1 

2 

3 

4 

5 

6 

1 

2 

3 

4 

5 

6 

1 

2 

3 

4 

5 

6 

1 

2 

3 

4 

5 

6 

1 

2 

3 

4 

5 

6 

AND C^ 

afte r 

n t o f 

tfl 

rA 

ta 

E 1-1 

c 

ta 

M-l 

o 

X 

(U 

CO 

? 

9 

9 

6 

6 

6 

9 

9 

9 

d 

6 

6 

9 

9 

9 

6 

6 

6 

.9 

9 

9 

6 

<J 

d 

9 

9 

9 

d 

d 

d 

rcLOPH( 

t h e s« 

cell s 

U) 

Q) 

• H 

-d 

o 

XI 

> i 

i H 

.-H 

0 

to 

0) 

r H 

O l 

c 

•rH 

W 

0 . 1 

0 . 1 

5 . 9 

5 . 4 

3 . 7 

8 . 0 

7 . 2 

9 . 1 

0 . 1 

0 . 1 

0 . 1 

0 . 3 

0 . 1 

0 . 1 

0 . 2 

0 . 2 

0 . 2 

DSPHAM 

scon d 

wit h 

•H 

0) 

f-l 

o 3 tn C Q) 

+ j 

m >, 

0 u 0 

CO u 

+J x: 

C +J 

Q) > i 

s ff Ol <u 

(0 

n c En -H 

2 . 1 

1 . 2 

0 . 3 

1 . 3 

1 . 0 

1 . 3 

No. 

[IDE ON BO 

applicat i 

anomalie s 

1 

o 

u 

Xi 

4-1 

> i 

U 

0) 

c 

•H 

•H 

tu 

r-{ 

o D 

C CO 

0 +J 

H 10 

CJ to 

•rl r-l 

S XI 

1 . 2 

I . O 

0 . 5 

2 . 4 

1 . 5 

1 . 8 

Df exp e 

OT; MAR5 

on 

o f nu c 

1 

o 

u 3 

0) 

rH 

C 

•rl Ul 

nH 

•H .H 

0) (U 

rH O 

CJ 

3 c; C -H 

0 +J 

M (U 

O -H 

•H O 

s a. 

0 . 1 

0 . 3 

0 . 2 

0 . 2 

0 . 1 

riment : 

OW_CELL§ 

l e i 

CO 

rH 

rH 

(U 

U 

Ti 

• H 

o 

rH 

a 

> 1 

rH 

o Cn 

0 . 2 

0 . 4 

0 . 1 

8 4 0 

;_gF 

.H 

Id 

+J 

O 

H 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

9 . 

8 . 

5 . 

1 1 . 

9 . 

1 2 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

0 . 

8 5 8 

0 

1 

1 

0 

o 

0 

3 

1 

1 

9 

8 

3 

1 

0 

1 

0 

1 

0 

3 

1 

1 

2 

0 

0 

2 

2 

0 

0 

0 

0 
Verteiler; 

HH,
QUALITY ASSURANCE STATEHENT 

Fom. 301 C 

STUDY TITLE : TK 12 443 (TINUVIN 234) 

NUCLEUS ANOMALY TEST IN SOMATIC INTERPHASE 

NUCLEI OF CHINESE HAMSTER 

Sponsor:

Study Ref./ Dispo.Nr.: 84085 8 

Study Director: QA Inspector N«wi 

THE QUALITY A55WANCE INSPECTION(S) WAS (WERE) PERFORMED ON THE FOLLOWING DATE(S) t 

01.10.8 4 

04.02.8 5 (Fina l repor t audit ) 

10 

11 

12 

13 

14 

15 

16 

17 

le 

THE FINDINGS WERE REPORTED TO THE STUDY DIRECTOR AND TD THE MANAGEMENT ON TWE FOLLOWING DATE(S) 

01.10.8 4 

04.02.8 5 

1 

2 

3 

4 

5 

6 

7 

e 

s 

QSE/OAU Keneger:

10 

11 

12 

13 

14 

15 

16 

17 

IB 

Dete: 04,02,8 5 Signeture:

DISTRIBUTION: ^ Study Director 

® GU 6.3 FUe 

SAV 103 C / Sep. 1983 
..o^ 
 Test No.: 840858 

Protection of Health 

and Environment 

GU 2.3 

Experimental Pathology 

NUCLEUS ANOMALY TEST IN SOMATIC INTERPHASE NUCLEI OF 

CHINESE HAMSTER 

Test material: TK 12 443 (TINUVIN 234) 

Supplement to the report (dated February 11, 1985) 

Date: May 26, 1987 
Additional data: Test No.: 840858 

Copies of raw data available from individual analysis records are 

attached to this supplement. 

\ Study Director:
KE RNANOMALIE-TEST Q NAT 20 CHA 

D NAT 12W CHA Versuchs-Nr. : "^^ CiSi .SV 

KERNANOMALIE-TEST 

Tier 

Nr. 

9 

k 

/ 

Tier 

Nr. 

1 * UL 

z 

Tier 

Nr. 

8 

UA 

Li 

1 Tier 

Nr. 

' 

[4 

y 

Tier 

Nr. 

1 ' 

\m A 

Tier 

Nr. 

)Hi. 

1 ^ 

Substanz : >k VVM,\-S 

Anomalien Typen 

Einzelne Jolly-K6rperchen 

Kerntrtliinier in Erythrozyten 

Kikiokerne in 

Erythroblastcn 

Hikirokerne in leukopoetlschen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KerntrOiMoer in Erythroryten 

Hikrokerne in 

Erythroblatten 

Hikrokeme in leukopoetiochen Zellen 

Polyplolde Zellen 

Einzelne Jolly-Urperchen 

KemtrOnmer in Erythroiyten 

Milurokeme in 

Erythroblasten 

Hikrokeme in leukopoetlschen Zellen 

Polyplolde Zellen 

Einzelne Jolly-XArperchen 

KerntrOnmer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-Mrperchen 

KemtrOnoier in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetlschen Zellen 

Polyplolde Zellen 

Einxelne Jolly-KSxperchen 

KemtrOaaer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Dosis: j'J. Versuchs-Datum: 

1 v.v«V . "^o- K - . '•'i -f 7c- C J"/ C 

Zahl de r Zelle n mit Anomalien 

i n IOOO ausgewertete n Zelle n 

V?, . . \ 

A 

k 

S . )vX. 

OA 

OJ 

y NAT 2D CHA 

Q NAT 12W CHA Versuchs-Nr, : '<'v ' 

Bemerkunqen: sieh e RUckseit e Sign.Auswerter:

Tier 

Nr. 

« 

V\l ^vi 

./ 

Tier 

Nr. 

> 

iM 

1 ^ 

Tier 

Nr. 

t 

'"{k 

3 

1 Tier 

Nr. 

1 ^ y\L 

Y 

Tier 

Nr. 

1 ^ 

m' 

«r 

Tier 

Nr. 

3 

M 

\ (. 

Substan z :~K V"L^>.C"i 

Anomalien Typen 

Einzelne Jolly-Kflrperchen 

KemtrOnoier in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoeti1 schen Zellen 

j Polyplolde Zellen 

Einzelne Jolly-Kflrperchen 

KerntrOasier in Erythrozyten 

1 Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-Karperchen 

KemtrOiuner in Erythrozyten 

Hikrokeme in 

Erythroblasten • 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtrOmaer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

. Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KerntrQiimer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KSzperchen 

Kemtrthaner In Erythrozyten | 

Hikrokeme in 1 

Erythroblasten 

Hikrokeme in leukopoetlschen Zellen | 

Polyplolde Zellen 

Dosis: f. . Versuchs-Datum:\ 

.•fjoi. .U.oJv> . 

Zahl de r Zelle n mit Anomalien 

1 i n 1000 ausgewertete n Zelle n 

11 

/'// 

1 1 

••^. . Vs 

S9 

11 

1 Vx 

Jl 

£^ 

^2 

y^ 

s 

^-

iH 

a 

r 

Z 

H 

'ao 

^i 

LK 

0. 

^Z 

y^ 

) r 

h 

^> 

y^\ 

y^ 

1 1 

. V.V .v>-

U-.'1 

l.k 

).X 

o.k 

^.M 

AX 

LO 

0,:^ 

o y 

'^^ 

o.'}. 

O.S 

o,^ 

OM 

'g.o 

V," ^ 

I.H 

0,2-: 

1 

-^x-l 

x.o i 

V,S : 

O.K 1 

^ A 1 

v ^ 

K,^ 

OA 1 

Bemerkunqen: sieh e RUckseit e SI o n . An^woTho r • V
KERN.^NOMALIE-TEST 0 NAT 2D CHA 

• NAT 12W CHA 

KE RNANOMALIE-TEST 

Versuchs-Nr.: ^*< C.\ ,CV 

Tier 

Nr. 

8 

Llo K\l~. 

/ 

Tier 

Mr. 

J ' V "^ 

1 2-

Tier 

Nr. 

> 

Pli 

.2 

1 Tier 

Nr. 

1 < 

K l\ l 

\ H^ 

1/ 

Tier 

Nr. 

S 

Ull 

r 

Tier 

N r. j 

<^l l 

^ 

1 H 

Substanz:"^ T^^^H^ 

Anomalien Typen 

Einzelne Jolly-KSrperchen 

I KemtrOmmer in Erythrozyten 

Hikrokeme in 

1 Erythroblasten 

Hikrokeme in leuXopoetiEchen Zellen 

Polyplolde Zellen 

Einzelne Jolly-Kfirperchen 

Kerntramoier in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtriJnaner in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetlschen Zellen 

Polyploids Zellen 

Einzelne Jolly-KSrperchen 

KemtrCmner in Erythrozyten 

Hikrokeme In 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Z«llen 

Einzelne Jolly-KOrperchen 

KemtrOamer in Erythrozyten 

Hikrokeme in | 

Erythroblasten 

Hikrokeme in leukopoeti- 1 

schen Zellen | 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtrOnmer in Erythrozyten | 

Hikrokeme in 1 

Erythroblasten 

Hikrokeme in leukopoctischen Zellen 

Polyplolde Zellen 

Dosis: C Versuchs-Datum: 

1 xT-'s.o ^•Ay., , 

Zahl der aellfn mit Anomalien 

in IOOO ausgewerteten Zellen 

fs. s\ 

1 r 

A 

A 

A 

^ . U .V 

O.I, 

0.). 

1 

O.X 1 

0 NAT 2D CHA 

• NAT 12W CHA Versuchs-Nr.: ^H <^^ SS. 

Bemerkunqen; siehe RUckseite Sign.Auswerter: ^^.-

Tier 

Nr. 

1 

h\i 

• ' ( 

Tier 

Nr. 

1 ' yV2. 

Tier 

Nr. 

1 ' K IA 

3 

Nr. 

1 ' 

\ % 

i\ 

Tier 

Nr. 

S 

1 1 \A r\ 

1 Tier 

Nr. 

Vfil 

1 (^ 1 

Substanz:lH (."i-^^a 

Anomalien Typen 

1 Einzelne Jolly-KOrperchen 

Kemtriliinier In Erythrozyten 

Hikrokeme in 

1 Erythroblastcn 

1 Hikrokeme in leukopoetl1 schen Zellen 

Polyplolde Zellen 

j Einzelne Jolly-KOrperchen 

I KerntrOmmer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetlschen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

Kemtrammer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyploids Zellen 

Einzelne Jolly-KOrperchen 

Kemtr<imiiier in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme In leukopoetiBchen Zellen 

Polyploids Zellen 

Einzelne Jolly-KOrperchen 

Kemtrflnmier in Erythrozyten 

Hikrokeme in 1 

Erythroblasten 

Hikrokeme in leukopoeti- 1 

schen Zellen { 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtriJniDer in Erythrozyten | 

Hikrokeme in 1 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen | 

Polyplolde Zellen 

Dosis: ^ . Versuchs-Datum: 

1 "V-^oO --V^ v 

Zahl der zfelldn mit Anomalien 

in 1000 ausgewerteten Zellen 

(\. . 

CL 

A 

A 

X. 

Xs.ix ; 

p.-v. 

o,\ 

(iA 

0,'^ 

Bemerkungen; siehe RUckseite Slqn. Auswert-pr; v.: 
KERNANOMALIE-TEST G] NAT 2D CHA 

• NAT 12W CHA Versuchs-Nr. : tV Ci'< !^"<: 

Tier 

Nr. 

» 

\\\ 

^ U 1 •' 

Tier 

Nr. 

J ' H 2-

Tler 

Nr. 

8 

/ L 

W1 -^ 

Nr. 

1 * 

. l l 1 

h^lA 

/ 

Ti e 

Nr. 

' 

h'li \h 

r 

1 Tier 

Nr. 

A^2. 

1 ^ 

Substanz : ' •' '' '"^•' 

Anomalien Typen 

Einzeloe Jolly-KOrperchen 

KerntrOoaer in Erythrozyten 

Hikrokeme in 

1 Erythroblasten 

Hikrokeme tn leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

Kemtr<tonier in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtrflBmer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtrQimoer in Erythrozyten 

Hikrokeme in 

Erythroblasten 

Hikrokeme in leukopoetischen Zellen 

Polyplolde Zellen ' 

Einzelne Jolly-KOrperchen 

Kemtrflnimer in Erythrozyten 

Hikrokeme in 1 

Erythroblasten 

Hikrokeme in leukopoeti- 1 

schen Zellen | 

Polyplolde Zellen 

Einzelne Jolly-KOrperchen 

KemtrflBDer in Erythrozyten | 

Hikrokeme in 1 

Erythroblasten 

Hikrokeme in leukopoeti- 1 

schen Zellen | 

Polyploids Zellen 

Dosis: C. , Versuchs-Datum: 

1 Sooo ^^^'-L. 

I Zahl de r ffellfen mit Anomalien 

i n 1000 ausgewertete n Zelle n 

\':> . , V 

X. 

"^ 

•V . ).->.. V ^ 

o.'i-. 

\y 

Bemerkunqen: sieh e RUckseit e Sign.Auswerter:

Da for.: ^'iV - ^a . -'^'-^ 
Verteiler: 

HH.